HomeNewscoronavirusCOVID-19 testing utilisation in private labs below 30%: Study

COVID-19 testing utilisation in private labs below 30%: Study

The study surveyed 50 private laboratories across 13 Indian states to explore ways to enhance testing in private sector labs.

May 28, 2020 / 20:19 IST
Story continues below Advertisement
Representative image
Representative image

While the cases of COVID-19 are rising, the capacity utilisation levels of private diagnostic laboratories for COVID-19 testing remains less than 30 percent, according to a study conducted by the NATHEALTH, the industry body that represents private healthcare providers.

The study surveyed 50 private laboratories across 13 Indian states to explore ways to enhance testing in private sector labs.

Story continues below Advertisement

The surveyed labs are currently working only single shifts, doing cumulative 5,000 RT-PCR tests per day with 17 labs doing less than 100 tests per day and 6 labs not doing any testing at all.

"A mere 30 percent utilisation of private labs also indicate demand flow as a challenge to enhance testing. The current testing regime prioritises demand flow to public labs with only excess demand flowing to private labs," the study said.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show